Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines
Muddasir Mohammed(University of Nottingham), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Poulam M. Patel(Nottingham University Hospitals NHS Trust), Charles A. Laughton, Rachel Abbotts(University of Nottingham), David M. Wilson(Hasselt University), Ian D. Hickson(University of Copenhagen), Vaddadi N. Vyjayanti(National Institute on Aging), Lodewijk V. Dekker(University of Nottingham), S Shah(University of Nottingham), Peter M. Fischer(University of Nottingham)
Cited by 71
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Hallmarks of neurodegenerative diseases
|Cell|2023|1.6k
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|605
Workgroup Report: Public Health Strategies for Reducing Aflatoxin Exposure in Developing Countries
|Environmental Health Perspectives|2006|537